Apogee Therapeutics (APGE) Common Equity (2022 - 2026)

Apogee Therapeutics (APGE) has reported Common Equity for 5 consecutive years, with $1.3 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity rose 86.5% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (up 86.5% YoY), while the FY2025 annual figure was $903.9 million, up 26.1% from the prior year.
• Common Equity climbed to $1.3 billion in Q1 2026 per APGE's latest filing, from $903.9 million in the prior quarter.
• Across five years, Common Equity topped out at $1.3 billion in Q1 2026 and bottomed at -$64.4 million in Q2 2023.
• Historically, Common Equity has averaged $480.0 million across 5 years, with a median of $602.9 million in 2025.
• Annual changes were most pronounced in 2023 — Common Equity tumbled 1353.08% — and 2024, when it soared 1818.32%.
• Apogee Therapeutics' Common Equity stood at -$35.4 million in 2022, then jumped by 1173.44% to $379.9 million in 2023, then soared by 88.67% to $716.8 million in 2024, then advanced by 26.1% to $903.9 million in 2025, then soared by 38.93% to $1.3 billion in 2026.
• Business Quant data shows APGE's Common Equity at $1.3 billion in Q1 2026, $903.9 million in Q4 2025, and $586.3 million in Q3 2025.